Texas Startup Makes Nuclear Breakthrough That Could Help Power Next Generation Reactors and Fight Cancer

Texas Nuclear Startup Makes Breakthrough Producing Critical Cancer Isotope and Next Generation Nuclear Fuel

A Texas nuclear technology startup has demonstrated a potentially important new method for producing two of the world’s most strategically valuable atomic materials: specialized isotopes used in advanced cancer treatments and high assay low enriched uranium needed to fuel many next generation nuclear reactors.

Plano area company Actinide Inc. says its first generation electromagnetic isotope separator, called Endurance, successfully enriched natural uranium into high assay low enriched uranium, better known as HALEU. Even more remarkably, the same machine had been producing enriched ytterbium 176 for the medical isotope industry only weeks before engineers reconfigured it to process uranium.

The accomplishment does not mean America has suddenly solved its nuclear fuel shortage. Actinide produced HALEU only in research quantities, and enormous technical, regulatory and economic hurdles remain before the company could manufacture reactor fuel at industrial scale. But the experiment demonstrates that a relatively compact electromagnetic separation system can be reconfigured to produce dramatically different high-value isotopes, potentially opening another domestic pathway for materials critical to nuclear medicine, advanced energy and national security.

Actinide Enriched Uranium to 15.38% U-235

Actinide announced on Aug. 26 that Endurance successfully enriched natural uranium to approximately 15.38% uranium 235, comfortably placing the material within the HALEU range. According to the company, the resulting material was analyzed by an independent ISO/IEC 17025 accredited laboratory. HALEU is uranium containing more than 5% but less than 20% uranium 235. Natural uranium contains only about 0.7% U 235, while fuel used by today’s conventional commercial nuclear reactors is generally enriched to approximately 3% to 5%. Uranium containing 20% or more U 235 crosses into the category of highly enriched uranium.

Many advanced reactor developers are designing systems around HALEU because its greater concentration of fissile uranium can enable smaller reactor cores, longer operating cycles, improved fuel utilization and potentially greater efficiency. That has made HALEU one of the most strategically important materials in America’s attempt to build a new generation of advanced nuclear reactors. Actinide’s demonstration was performed in research quantities under a laboratory-scale exclusion in federal nuclear regulations. The company has therefore demonstrated uranium enrichment into the HALEU range, but it has not established a commercial HALEU production facility.

The Technology Has Roots in the Manhattan Project

Actinide’s approach is particularly interesting because the company is not relying on the gas centrifuge technology that dominates modern commercial uranium enrichment. Instead, Endurance is a modern electromagnetic isotope separator based on the same fundamental physics used by the massive calutrons developed during the Manhattan Project.

The underlying principle is relatively straightforward even if the engineering required to accomplish it is not. Material is heated and ionized, producing electrically charged particles that are accelerated into a beam. That beam travels through a powerful magnetic field, which bends the trajectories of the ions. Because isotopes of the same element have slightly different masses, their paths curve differently, allowing specific isotopes to be physically separated and collected.

Modern vacuum systems, magnets, electronics, computer modeling and precision controls allow Actinide to use a concept developed more than 80 years ago in a substantially smaller and more flexible machine. Reports describing the particles as traveling at or near the speed of light oversimplify the physics. The system does not depend on relativistic particle speeds. What matters is creating and controlling an ion beam so the magnetic field can separate isotopes according to their mass-to-charge ratios.

The Same Machine Produces a Critical Cancer Treatment Isotope

Before Actinide turned Endurance toward uranium, the machine was already producing enriched ytterbium 176, or Yb 176, a valuable stable isotope used as precursor material for producing lutetium 177. Actinide says it has produced and sold ytterbium enriched to greater than 95% Yb 176 and completed a bulk delivery to Oklo Isotopes shortly before the uranium experiment. FOX 4 Dallas Fort Worth reported that Yb-176 can be worth approximately $30,000 per gram, illustrating the extraordinary economics surrounding specialized isotope production.

Ytterbium 176 is particularly important because it can be irradiated to produce lutetium 177, a radioactive isotope increasingly used in radiopharmaceutical cancer treatments. These therapies represent one of the fastest developing areas of oncology because they can carry radioactive material directly to specific biological targets associated with cancer cells. Rather than directing radiation toward a tumor entirely from outside the body, targeted radiopharmaceuticals combine a radioactive isotope with a molecule designed to seek a particular target. Once the drug reaches and binds to cancer cells, the radioactive payload can damage those cells from extremely close range.

Lutetium 177 is already being used in approved cancer treatments, including Novartis’ Pluvicto for certain forms of prostate cancer. The expanding market for these treatments is increasing demand for the specialized isotopes required to manufacture them and intensifying concern over the security of the international supply chain.

One Machine Could Potentially Serve Multiple Atomic Industries

The larger technological breakthrough may therefore be Endurance’s flexibility rather than the small amount of HALEU produced during the experiment. Actinide demonstrated that the same underlying machine used to manufacture commercially valuable Yb-176 could be reconfigured within weeks to separate uranium isotopes and enrich natural uranium into the HALEU range. That could potentially give the company’s technology applications across nuclear medicine, advanced nuclear energy, scientific research and other industries requiring highly enriched stable or radioactive-isotope precursors.

Traditional isotope production infrastructure can be extremely expensive and specialized. Actinide is betting that modern electromagnetic separation can become more compact, modular and adaptable, allowing individual machines to be reconfigured depending on which isotopes are needed. The company is now building a second generation electromagnetic separator called Fortitude. Actinide estimates that one Fortitude machine could eventually provide roughly half the isotope-separation throughput of the U.S. government’s existing electromagnetic fleet. That remains a company projection rather than an independently demonstrated production figure, but it illustrates the scale of Actinide’s ambitions.

America’s HALEU Supply Problem Is Already a National Priority

Actinide’s breakthrough arrives as the federal government is spending billions of dollars attempting to build precisely the type of domestic nuclear fuel supply chain that the company’s technology could eventually support.

The Department of Energy says the United States currently has limited commercial HALEU enrichment services available to support advanced reactor deployment. In January 2026, DOE announced $2.7 billion in task orders aimed at expanding domestic uranium-enrichment capacity over the next decade. American Centrifuge Operating, a Centrus Energy subsidiary, received $900 million to expand HALEU enrichment capacity, while General Matter received another $900 million for domestic HALEU enrichment. Orano Federal Services received $900 million to expand conventional low-enriched uranium capacity.

The government is spending that money because many advanced nuclear-reactor projects cannot reach meaningful commercial deployment without a reliable supply of fuel. The United States is not starting from zero. Centrus began producing HALEU at its Piketon, Ohio, demonstration cascade in 2023 and had produced approximately 900 kilograms by June 2025 under its Department of Energy program. The NRC currently identifies Centrus and Louisiana Energy Services as companies holding licenses allowing HALEU production at specified enrichment levels and quantities. That distinction is important when evaluating Actinide’s announcement. The Texas company is not claiming to have surpassed Centrus in commercial-scale production. Its breakthrough is the demonstration of a different enrichment technology capable of reaching the HALEU range using a compact electromagnetic separator that can also manufacture other valuable isotopes.

America’s Foreign Nuclear Fuel Dependence Makes the Technology Strategically Important

The broader geopolitical problem extends beyond any single company. For decades, the United States allowed significant portions of its nuclear-fuel supply chain to migrate overseas. Russia became a particularly important supplier of uranium enrichment services, creating an obvious strategic vulnerability as relations between Washington and Moscow deteriorated.

The federal government has responded by restricting Russian uranium imports and investing heavily in rebuilding domestic uranium conversion, enrichment, deconversion and fuel-fabrication infrastructure. DOE’s multibillion dollar enrichment program is designed specifically to reduce foreign dependence while creating enough domestic capacity to supply both America’s existing reactor fleet and advanced reactors now under development.

Specialized medical isotopes present a similar challenge. Many isotopes essential to medicine, research and advanced manufacturing depend on highly concentrated global supply chains. A disruption at a small number of facilities can therefore ripple through hospitals, pharmaceutical manufacturers and research institutions around the world. Actinide’s argument is that the United States should be capable of manufacturing these strategic atomic materials domestically rather than depending on foreign suppliers for materials essential to cancer treatments and nuclear energy.

Producing HALEU Is Not the Same as Producing Reactor Fuel

The limitations of the breakthrough are just as important as the accomplishment itself. Producing a research quantity of uranium enriched to 15.38% U 235 proves that Actinide’s machine can perform the isotope separation required to reach the HALEU range. It does not prove that the company can economically manufacture kilograms or metric tons of HALEU under commercial operating conditions.

A functioning nuclear fuel supply chain involves far more than enrichment. Uranium must be processed into appropriate chemical and physical forms, fabricated into reactor specific fuel such as pellets, rods or TRISO particles, transported under strict security requirements and manufactured under extensive nuclear quality-assurance and regulatory standards. Actinide itself acknowledges that its experimental HALEU would still require fuel fabrication before it could ever be placed inside a reactor.

Commercial expansion would also bring substantially greater NRC oversight, safeguards, material-accounting requirements, security obligations and licensing hurdles than those governing the company’s laboratory scale experiment. The technology has therefore crossed an important scientific and engineering threshold, not the finish line.

The Bigger Breakthrough Could Be a New American Isotope Manufacturing Platform

What makes Actinide worth watching is the combination of accomplishments rather than any single experiment. The company built a modern electromagnetic isotope separator, used it to produce highly enriched ytterbium 176, delivered material commercially, reconfigured the same machine and then demonstrated enrichment of natural uranium to approximately 15.38% U 235. That sequence suggests the technology could eventually become something broader than another uranium enrichment system. It could become a flexible manufacturing platform for producing specialized isotopes across multiple industries.

Actinide is now attempting to scale Yb 176 production from gram quantities toward kilograms while simultaneously developing larger electromagnetic separators and pursuing the regulatory path necessary for expanded nuclear applications. There is still an enormous distance between producing grams of valuable isotopes in Texas and supplying America’s pharmaceutical and nuclear industries at scale. Centrifuge enrichment remains vastly more mature for bulk uranium production, and Actinide will ultimately have to prove that electromagnetic separation can compete economically outside specialized, extremely high-value isotope markets. But the demonstration addresses a real strategic problem.

America needs more domestic sources of specialized isotopes. It needs significantly more HALEU if advanced nuclear reactors are going to be deployed at the scale developers envision. It needs more secure medical-isotope supply chains as targeted radiopharmaceutical cancer treatments expand. And it needs technologies capable of producing those materials without relying heavily on geopolitical competitors. Actinide has not solved those problems yet. What it has demonstrated in Texas is that one modern electromagnetic separation platform can manufacture a valuable medical isotope and then be reconfigured to enrich uranium into the range required by many advanced reactors.

If the company can successfully scale that technology from laboratory and early commercial quantities into reliable industrial production, a machine whose underlying physics dates to the Manhattan Project could become part of one of America’s most important 21st century nuclear supply chains.

Sources

Primary Reporting and Company Documentation

Actinide Inc. — “Actinide Becomes First Startup to Ever Enrich Uranium, Producing HALEU”
Actinide’s Aug. 26, 2026 announcement detailing the Endurance electromagnetic separator, 15.38% U-235 enrichment result, Yb-176 production and development of its second-generation Fortitude system. (Actinide Inc.)

U.S. Nuclear Regulatory Commission

NRC — High-Assay Low-Enriched Uranium (HALEU)
Official federal overview of HALEU, including its 5%–20% U-235 definition, advanced-reactor applications, potential efficiency advantages and current U.S. enrichment licensing. (Nuclear Regulatory Commission)

NRC — Centrus Energy and American Centrifuge Operating Licensing
Official licensing history and technical information covering Centrus’ HALEU enrichment operation in Piketon, Ohio. (Nuclear Regulatory Commission)

U.S. Department of Energy

Department of Energy — HALEU Enrichment Services
DOE’s official overview of the federal effort to establish a larger domestic supply of HALEU for advanced nuclear reactors. (The Department of Energy’s Energy.gov)

Department of Energy — $2.7 Billion to Restore American Uranium Enrichment
Details the January 2026 federal awards, including $900 million each for American Centrifuge Operating and General Matter to develop domestic HALEU enrichment capacity. (The Department of Energy’s Energy.gov)

Department of Energy — Centrus Reaches 900 Kilograms of HALEU Production
Confirms that Centrus had already produced approximately 900 kilograms of HALEU in Ohio by June 2025, an important distinction when describing Actinide’s 2026 breakthrough. (The Department of Energy’s Energy.gov)

Department of Energy — HALEU Technologies Program
Federal information on emerging enrichment technologies and DOE efforts to develop additional American HALEU production methods. (The Department of Energy’s Energy.gov)

Department of Energy — Centrus Produces Nation’s First Amounts of HALEU
Documents the beginning of U.S. HALEU production at Centrus’ Ohio facility and explains why the material is critical to many advanced-reactor designs. (The Department of Energy’s Energy.gov)